Product Certification&
    Enterprise Certification

  • Mr.eric
    Tel: 86-21-58090396-805

  • Mobile:18501659228
  • Tel:86-21-58090396-805
  • Fax:+86-21-33250189
  • URL:
  • Province/state:shanghai
  • City:shanghai
  • Street:Floor 4, Building 5, No.588 Tianxiong Road, Zhoupu International Medical Zone, ShangHai, China
  • MaxCard:
Home > Products >  Obeticholic Acid

Obeticholic Acid CAS NO.459789-99-2

  • msdsMSDS/COA Download

  • FOB Price: USD: /Kilogram Get Latest Price
  • Min.Order: 1 Gram
  • Payment Terms: L/C,D/A,T/T,Western Union,MoneyGram,Other
  • Available Specifications:


  • Product Details


  • 6-Ecdca
  • C15636
  • (3α,5β,6α,7α)-6-ethyl-3,7-dihydroxy-cholan-24-oic acid

Quick Details

  • ProName: Obeticholic Acid
  • CasNo: 459789-99-2
  • Molecular Formula: C26H44O4
  • Appearance: white powder
  • Application: pharmaceutical intermediate
  • DeliveryTime: depend on the quantity
  • PackAge: PE bag and AL bag, PE bottle
  • Port: any port
  • ProductionCapacity: 30 Kilogram/Month
  • Purity: 99%+
  • Storage: Below 25℃
  • Transportation: DHL or Fedex
  • LimitNum: 1 Gram
  • Related Substances: NMT 1.0%
  • Residue on Ignition: NMT 0.5%
  • Heavy Metal: 20ppm
  • Valid Period: 2years


We have co-operate with our own GMP plant. For this product,we can provide the DMF for customer .

Hope Chem is dedicated to manufacturing, marketing and CMO service of Active Pharmaceutical Ingredients (APIs), Intermediates and Specialty Chemicals since year 2010. Currently we have exclusive partnerships with multiple, state of the art and GMP compliant manufacturers in China and abroad to service our esteemed partners for competitive, long-term & stable supplies.

In China, we currently have Anti-Cancer and ARVs APIs GMP plants and factory which are USFDA and EDQM quality system compliant and we also have specialized fluorine series compounds to cater to global customers for their specialized and customized products in line with the desired quality assurance systems.
We have professional GMP laboratories and GMP factory in Anhui province. All our facilities have established strict quality controland assurance systems and a series of standard operation procedures (SOPs) forthe whole supply chain from raw material procurement to finished goods delivery.


Obeticholic acid is a semi-synthetic bile acid analogue and acts as a farnesoid-X receptor (FXR) agonist. It is used for the treatment of primary biliary cholangitis. It is also under investigation for the treatment of other liver diseases,primary biliary cirrhosis, bile acid diarrhea and related disorders. Study has shown that it also has potential for treating nonalcoholicsteatohepatitis (NASH), and portal hypertension. Obeticholic acid takes effect through acting s the agonist of the farnesoid X receptor (FXR), which is the regulator of bile and cholesterol metabolism in the liver. 
Obeticholic acid is also called 6-Ethylchenodeoxycholic acid. It is a new derivative of chenodeoxycholic acid (CDCA) in human primary bile acids, a natural ligand for farnesoid x receptors (FXR). Obeticholic acid was developed by American pharmaceutical company Intercept as the first drug to treat cholestatic liver disease in 20 years, and it is administered on patients that do not respond well to or cannot tolerate the old standard treatment drug ursodeoxycholic acid. Obeticholic acid has also been tested to treat a more common form of fatty liver – non-alcoholic fatty liver disease (NAFLD). Obeticholic acid can also be developed to treat other liver and intestine diseases.
Obeticholic acid belongs to FXR stimulants, activating FXRs and indirectly inhibiting Cytochrome P450 Family 7 Subfamily A Member 1 (CYP7A1) expression. As CYP7A1 is a rate-limiting enzyme of bile acid biosynthesis, obeticholic acid can inhibit the bile acid synthesis and is used to treat primary biliary cirrhosis.
Clinical Research In a placebo control phase III clinical trial, Obeticholic acid increased levels of two biomarkers indicating lowered risk in liver transplant. The composite end point of the clinical research is that alkaline phosphatase lowered by at least 15%, serum alkaline phosphatase activity was 1.67 times lower than the normal upper limit, and bilirubin levels were within normal range; alkaline phosphatase is a biomarker indicating liver disease severity. An American 6-week, multi-center, randomized, and double-blind clinical trial included 64 cases of type 2 diabetes patients with NAFLD, and it proved that Obeticholic acid not only increased insulin sensitivity, but also improved liver inflammation and fibrosis levels, and it has certain weight-reducing effects. However, this conclusion requires further investigation with a larger and more long-term follow-up, as well as scientific backing in liver pathology.
hetic bile acid which acts as a farnesoid X receptor agonist and is used for treatme t of primary biliary cholangitis.

Other products of this supplier

lookchemhot product CAS New CAS